Literature DB >> 9632993

Humoral immunity to HIV, SIV, and SHIV.

N L Haigwood1, S Zolla-Pazner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9632993

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.

Authors:  K Mori; Y Yasutomi; S Ohgimoto; T Nakasone; S Takamura; T Shioda; Y Nagai
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Evidence for early local viral replication and local production of antiviral immunity upon mucosal simian-human immunodeficiency virus SHIV(89.6) infection in Macaca nemestrina.

Authors:  Z Ambrose; K Larsen; J Thompson; Y Stevens; E Finn; S L Hu; M L Bosch
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation.

Authors:  Kimdar Sherefa Kemal; Brian Foley; Harold Burger; Kathryn Anastos; Howard Minkoff; Christina Kitchen; Sean M Philpott; Wei Gao; Esther Robison; Susan Holman; Carolyn Dehner; Suzanne Beck; William A Meyer; Alan Landay; Andrea Kovacs; James Bremer; Barbara Weiser
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

5.  Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

Authors:  Nancy L Haigwood; David C Montefiori; William F Sutton; Janela McClure; Andrew J Watson; Gerald Voss; Vanessa M Hirsch; Barbra A Richardson; Norman L Letvin; Shiu-Lok Hu; Philip R Johnson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.

Authors:  Simon M Agwale; Joseph C Forbi; Frank Notka; Terri Wrin; Jens Wild; Ralf Wagner; Hans Wolf
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.